Biocon is an important strategic partner and we would look for opportunities to expand the partnership, said Rajiv Malik, President, Mylan.
Malik said both the companies have already expanded the partnership recently to add two more products.
The US Food and Drug Administration (USFDA) has approved Mylan's cancer treating biosimilar Fulphila co-developed with Biocon.
Speaking exclusively to CNBC-TV18, he said, "It's huge moment for Mylan-Biocon partnership, because it validates our commitment to affordability and accessibility. Very excited to get another first in US market after the approval for our biosimilar Herceptin."
However, he clarified that there are no talks of buying any stake in
When asked if these approvals from USFDA would make them more acceptable to doctors, insurance community, administration in the US, he said that is the hope and they are working towards it.
"We see lot of excitement in the medical community about the acceptance of these product,” he added.
With regards to warning letter for Nashik facility, Malik said the facility has been audited and the issue would be behind us soon.
On the pricing front, he said they see stabilization coming in on pricing in the US.